Genetics of hypertension. Therapeutic implications

Drugs

Volumn 56, Issue 2, 1998, Pages 203-214

  O'Byrne, Sharon ^a   Caulfield, Mark ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; DIURETIC AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTICLE; ESSENTIAL HYPERTENSION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INHERITANCE; LIDDLE SYNDROME; MAJOR CLINICAL STUDY; PSEUDOHYPOALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM TRANSPORT;

EID: 0031871488     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00004     Document Type: Article

References (51)

1. Lander ES, Schork NJ. Genetic dissection of complex traits [published erratum appears in Science 1994 Oct 21; 266 (5184): 353] [review]. Science 1994 Sep 30; 265 (5181): 2037-48
2. Dykes CW. Genes, disease and medicine. Br J Clin Pharmacol 1996 Dec; 42 (6): 683-95
3. Lifton RP. Molecular genetics of human blood pressure variation [review]. Science 1996 May 3; 272 (5262): 676-80
4. Ward R. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. Vol. 1. New York; Raven Press, 1990: 81-100
5. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966 Nov 26; 95 (22): 1109-19
6. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992 Jan 16; 355 (6357): 262-5
7. White PC. Inherited forms of mineralocorticoid hypertension. Hypertension 1996 Dec; 28 (6): 927-36
8. Mune T, Rogerson FM, Nikkila H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995 Aug; 10 (4): 394-9
9. Stewart PM, Krozowski ZS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996 Jan 13; 347 (8994): 88-91
10. Liddle GW, Bledsoe T, Coppage WS. A familial renal disorder stimulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963; 76: 199-213
11. Shimkets R, Warnock DG, Bositis CM, et al. Liddles syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994 Nov 4; 79 (3): 407-14
12. Gordon RD, Geddes RA, Pawsey CG, et al. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970 Nov; 19 (4): 287-94
13. Mansfield TA, Simon DB, Farfel Z, et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 1997 Jun; 16 (2): 202-5
14. Julier C, Delepine M, Keaveney B, et al. Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet 1997 Nov; 6 (12): 2077-85
15. Kaplan NM, Ram CVS. Hypertension in ethnic sub-groups. In: Swales JD, editor. Textbook of hypertension. Oxford: Blackwell, 1994: 811-28
16. O'Connor DT, Kailasam MT, Parmer RT. Complex trait genetics: new methods yield a result for essential hypertension [editorial]. J Clin Invest 1996 May 1; 97 (9): 1997-8
17. Brown MJ. The causes of essential hypertension. Br J Clin Pharmacol 1996 Jul; 42 (1): 21-7
18. Risch N, Zhang H. Extreme discordant sib pairs for mapping quantitative trait loci in humans. Science 1995 Jun 16; 268 (5217): 1584-9
19. Bennett ST, Lucassen AM, Gough FC et al. Susceptibility to human type 1 diabetes at IDDM 2 is determined by tandem repeat variation at the insulin gene mini satellite locus. Nature Genetics 1995; 9: 284-92
20. Reed PW, Davies JL, Copeman JB, et al. Chromosome-specific microsatellite sets for fluorescence-based, semi-automated genome mapping. Nat Genet 1994 Jul; 7 (3): 390-5
21. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches. Proc Natl Acad Sci U S A 1995 Sep 12; 92 (19): 8560-5
22. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of hypertension: role of angiotensinogen. Cell 1992 Oct 2; 71 (1): 169-80
23. Caulfield M, Lavender P, Farrall M, et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994 Jun 9; 330 (23): 1629-33
24. Caulfield M, Lavender P, Newell-Price J, et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995 Aug; 96 (2): 687-92
25. Schunkert H, Hense H-W, Gimenez-Roqueplo A, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population-based cohort. Hypertension 1997 Feb; 29 (2): 628-33
26. Hingorani AD, Sharma P, Jia H, et al. Blood pressure and the M235T polymorphism of the angiotensinogen gene. Hypertension 1996 Nov; 28 (5): 907-11
27. Jeunemaitre X, Inoue I, Williams C, et al. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet 1997 Jun; 60 (6): 1448-60
28. Inoue I, Nakojima T, Williams CS. et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects hasal transcription in vitro. J Clin Invest 1997 Apr 1; 99 (7): 1786-97
29. Ishigami T, Umemura S, Tamura K, et al. Essential hypertension and 5′upstream core promoter region of human angiotensinogen gene. Hypertension 1997 Dec; 30 (6): 1325-30
30. Dudley C, Keavney B, Casadei B, et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens 1996 Feb; 14 (2): 259-62
31. Hingorani AD, Jia H, Stevens P, et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995 Dec; 13 (12 Pt 2): 1602-9
32. Dieguex-Lucena JL, Aranda-Lara P, Ruiz-Galdon M, et al. Angiotensin I-converting enzyme genotypes and angiotensin II receptors - response to therapy. Hypertension 1996 Jul; 28 (1): 98-103
33. Sasaki M, Takashi O, Luchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed doppler echocardiographic studies. J Hypertens 1996 Dec; 14 (12): 1403-8
34. Zee RYL, Lou YK, Morris BJ. Association of a polymorphism of the angiotensin I-converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1991 Apr 15; 184 (I): 9-15
35. Jeunemaitre X, Lifton RP, Hunt SC, et al. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1992 Apr; 1 (1): 72-5
36. Schmidt S, van Hooit MS, Grobbee DE, et al. Polymorphism of the angiotensin I converting enzyme gene is apparently not related to high blood pressure: Dutch Hypertension and Offspring study. J Hypertens 1993 Apr; 11 (4): 345-8
37. Harrap SB, Davidson HR, Connor JM, et al. The angiotensin I converting enzyme gene and predisposition to high blood pressure. Hypertension 1993 Apr; 21 (4): 455-60
38. Bonnardeaux A, Davies E, Jeunemaitre X, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994 Jul; 24 (1): 63-9
39. Benetos A, Gautier S, Ricard S, et al. Influence of angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphisms on aortic stiffness in normotensive and hypertensive patients. Circulation 1996 Aug 15; 94 (4): 698-703
40. Benetos A, Cambien F, Gautier S, et al. Influence of angiotensin II type I receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996 Dec; 28 (6): 1081-4
41. 2c10-adrenergic receptor genotype. Hypertension 1996 Jun; 27 (6): 1210-5
42. 2-adrenoceptor. Hypertension 1997 Oct; 30 (4): 773-6
43. Lang CC, Stein M, Brown M, et al. Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med 1995 Jul 20; 333 (3): 155-60
44. Bianchi G, Tripodi G, Casari G, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci U S A 1994 Apr 26; 91 (9): 3999-4003
45. Tripodi G, Valtorta F, Torielli L, et al. Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996 Jun 15; 97 (12): 2815-22
46. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha adducin and salt sensitivity in patients with essential hypertension. Lancet 1997 May 10; 349 (9062): 1353-7
47. Rosskopf D, Dusing R, Siffert W. Membrane sodium-proton exchange in primary hypertension. Hypertension 1993; 21: 607-17
48. Siffert W, Rosskopf D, Siffert G, et al. Association of a human G-protein β3 subunit variant with hypertension. Nat Genet 1998; 18: 45-8
49. Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension 1997 Jan; 29 (1 Pt 2): 177-87
50. Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995 Jul; 26 (1): 131-6
51. 1-R mRNA antisense. Hypertension 1997 Jan; 29 (1 Pt 2): 374-80